Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.60 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.60 |
| ▸ | TNF | P01375 | 3/20 | 0.60 |
| ▸ | IL1B | P01584 | 3/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23065966 | 0.84 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19248974 | 0.84 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29878132 | 0.84 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21602693 | 0.84 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25423114 | 0.84 | CRBN (0.65) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL1499656 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL6180704 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL6178113 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29943635 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL19278144 | 0.82 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015110659-A1 | METHODS OF IMMUNIZATION WITH A VACCINE INDUCING A HUMORAL IMMUNE RESPONSE AND WITH A VACCINE INDUCING A CELLULAR IMMUNE RESPONSE | BIONOR IMMUNO AS (NO) | 2015-07-30 | — | — | WO | claimed |
| EP-2301535-A1 | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy | CELGENE CORPORATION (US) | 2011-03-30 | — | — | EP | claimed |
| US-20210163442-A1 | CRYSTALLINE FORMS OF LENALIDOMIDE | BIOCON LIMITED (IN) | 2021-06-03 | — | — | US | disclosed |
| EP-3524253-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS | Celularity, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10001483-B2 | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | CELGENE CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3182996-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170157103-A1 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA USING 3-(4-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | CELGENE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| CN-103393681-B | Methodand composition for treatment and management of multiple myeloma | 细胞基因公司 | 2017-04-12 | — | — | CN | disclosed |
| WO-2016029004-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | CELGENE CORPORATION (US) | 2016-02-25 | — | — | WO | disclosed |
| EP-2981262-A1 | METHODS AND COMPOSITIONS USING 4-AMINO-2-(2,6-DIOXO-PIPERIDINE-3-YL)-ISOINDOLINE-1,3-DIONE FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM CANCERS | Celgene Corporation (US) | 2016-02-10 | — | — | EP | disclosed |
| CN-105246480-A | Methods and compositions for treating and controlling central nervous system cancer using 4-amino-2- (2, 6-dioxo-piperidin-3-yl) -isoindoline-1, 3-dione | CELGENE CORP | 2016-01-13 | — | — | CN | disclosed |
| WO-2014165482-A1 | METHODS AND COMPOSITIONS USING 4-AMINO-2-(2,6-DIOXO-PIPERIDINE-3-YL)-ISOINDOLINE-1,3-DIONE FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM CANCERS | CELGENE CORPORATION (US) | 2014-10-09 | — | — | WO | disclosed |
| CN-103097520-A | Method for producing natural killer cells | ANTHROGENESIS CORP | 2013-05-08 | — | — | CN | disclosed |
| EP-2504703-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE RESTORATION OF VITAMIN D SENSITIVITY IN VITAMIN D RESISTANT TUMOR CELLS | Celgene Corporation (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2012078492-A1 | A COMBINATION THERAPY WITH LENALIDOMIDE AND A CDK INHIBITOR FOR TREATING MULTIPLE MYELOMA | CELGENE CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011066351-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE RESTORATION OF VITAMIN D SENSITIVITY IN VITAMIN D RESISTANT TUMOR CELLS | CELGENE CORPORATION (US) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011066351-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE RESTORATION OF VITAMIN D SENSITIVITY IN VITAMIN D RESISTANT TUMOR CELLS | CELGENE CORPORATION (US) | 2011-06-03 | — | — | WO | disclosed |
| EP-1933818-B1 | METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LOW PLASMA LEPTIN LEVELS | CELGENE CORP (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009105256-A2 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CELGENE CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009061445-A2 | USE OF IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | CELGENE CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10001483-B2 | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | BCL6, MALT1, BCL3 | CRBN 1487/4885DDB1 100/4885IKZF3 46/4885 |
| US-20210163442-A1 | CRYSTALLINE FORMS OF LENALIDOMIDE | CRBN, SALL4, RDX | CRBN 1/4885DDB1 235/4885IKZF3 1856/4885 |
| US-20170157103-A1 | METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA USING 3-(4-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE | BCL6, BCL3, MALT1 | CRBN 745/4885DDB1 96/4885IKZF3 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.